SMPD2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL29471138	1.00	2/20
SCHEMBL360960	0.59	2/20
SCHEMBL611869	0.59	2/20
SCHEMBL4234738	0.59	2/20
SCHEMBL4239949	0.59	2/20
SCHEMBL8340882	0.59	2/20
SCHEMBL8341673	0.59	2/20
SCHEMBL13930310	0.59	2/20
SCHEMBL13930311	0.59	2/20
SCHEMBL13930314	0.59	2/20
SCHEMBL8844798	0.58	2/20
SCHEMBL18248611	0.58	2/20
SCHEMBL28708757	0.56	2/20
SCHEMBL9215539	0.56	2/20
SCHEMBL9998150	0.56	2/20
SCHEMBL9998152	0.56	2/20
SCHEMBL11325317	0.56	2/20
SCHEMBL11325321	0.56	2/20
SCHEMBL11325323	0.56	2/20
SCHEMBL4786264	0.55	2/20

Clinical trials — most relevant to SMPD2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency	PHASE2	COMPLETED
Ambroxol as a Treatment for Parkinson's Disease Dementia	PHASE2	UNKNOWN
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia	PHASE1/PHASE2	COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides	PHASE1	COMPLETED
National Multicentre Study of the Natural History of Acid Sphingo-myelinase Deficiency in Adults and Children	nan	NOT_YET_RECRUITING
Study of the Prevalence of Acid Sphingomyelinase Deficiency/Niemann Pick AB and B Disease in Patients With Diffuse Interstitial Lung Disease	nan	NOT_YET_RECRUITING
Screening for Gaucher Disease and Acid Sphingomyelinase Deficiency	nan	NOT_YET_RECRUITING
Studying Lipids as Potential Biomarkers in Patients With Fabry Disease	nan	COMPLETED
High-Density Lipoprotein (HDL) Treatment Study	nan	COMPLETED
Biomarkers Of Lung InVolvement In ASMD	nan	UNKNOWN
Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes	nan	COMPLETED
Biomarker for Farber Disease (BioFarber)	nan	WITHDRAWN
Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans	nan	COMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Registry Gangliosidoses	nan	UNKNOWN
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)	nan	RECRUITING
Diagnostic Creteria of Acid Sphingomyelinase Deficiency (ASMD)	nan	ACTIVE_NOT_RECRUITING
A Prospective and Retrospective Cohort Study in Patients With Chronic Forms of Acid Sphingomyelinase Deficiency (ASMD)	nan	COMPLETED
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)	nan	WITHDRAWN
The ASTERS Study: Assessing the Role of Sphingolipids in AcuTE Respiratory Distress Syndrome (ARDS)	nan	COMPLETED
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders	nan	RECRUITING
Precision Medicine for Sng/Pain Control	nan	COMPLETED
Effect of Plasma Ceramides on Peripheral Vascular Function	nan	COMPLETED
Genetic Studies of Lysosomal Storage Disorders	nan	ENROLLING_BY_INVITATION
Role of PLA2G1B During HIV Infection	nan	UNKNOWN
Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase Deficiency (ASMD)	nan	APPROVED_FOR_MARKETING
Molecular Markers of Human Sperm Function	nan	WITHDRAWN
Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a SMPD2 binder may also engage these)

Protein	Name	Similarity
O70572	—	0.995	O70572 →
Q9ET64	—	0.992	Q9ET64 →
D6MZJ6	—	0.972	D6MZJ6 →
P79942	—	0.971	P79942 →
O43304	—	0.969	O43304 →
FLAD1	FAD synthase	0.967	landscape →
MAP3K6	Mitogen-activated protein kinase kinase kinase 6	0.967	landscape →
Q2QDF0	—	0.967	Q2QDF0 →
P51839	—	0.966	P51839 →
Q9D7J6	—	0.966	Q9D7J6 →
P51840	—	0.966	P51840 →
P49184	—	0.966	P49184 →
Q68DD2	—	0.965	Q68DD2 →
Q7TNJ2	—	0.965	Q7TNJ2 →
Q643R3	—	0.965	Q643R3 →
Q9CTG6	—	0.965	Q9CTG6 →
P48760	—	0.965	P48760 →
Q9NNW5	—	0.965	Q9NNW5 →
Q9HCU5	—	0.965	Q9HCU5 →
ERN2	Serine/threonine-protein kinase/endoribonuclease IRE2	0.964	landscape →
Q9Z2E3	—	0.964	Q9Z2E3 →
P51689	—	0.964	P51689 →
Q9ET55	—	0.964	Q9ET55 →
Q865R1	—	0.964	Q865R1 →
Q8BYR1	—	0.964	Q8BYR1 →
Q9WTR2	—	0.964	Q9WTR2 →
A7E3S5	—	0.964	A7E3S5 →
RNF31	E3 ubiquitin-protein ligase RNF31	0.964	landscape →
Q6P5W5	—	0.963	Q6P5W5 →
Q5T3U5	—	0.963	Q5T3U5 →